Cargando…
Evaluating the Role of the Interleukin-23/17 Axis in Critically Ill COVID-19 Patients
Studies have hypothesized a potential role of the interleukin (IL)-23/17 axis in coronavirus disease 2019 (COVID-19). However, to date, levels of IL-23 and 17 have not been compared between critically ill COVID-19 patients and critically ill non-COVID-19 patients. IL-23 and 17 were measured on admis...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8466794/ https://www.ncbi.nlm.nih.gov/pubmed/34575667 http://dx.doi.org/10.3390/jpm11090891 |
_version_ | 1784573231114485760 |
---|---|
author | Jahaj, Edison Vassiliou, Alice G. Keskinidou, Chrysi Gallos, Parisis Vrettou, Charikleia S. Tsipilis, Stamatios Mastora, Zafeiria Orfanos, Stylianos E. Dimopoulou, Ioanna Kotanidou, Anastasia |
author_facet | Jahaj, Edison Vassiliou, Alice G. Keskinidou, Chrysi Gallos, Parisis Vrettou, Charikleia S. Tsipilis, Stamatios Mastora, Zafeiria Orfanos, Stylianos E. Dimopoulou, Ioanna Kotanidou, Anastasia |
author_sort | Jahaj, Edison |
collection | PubMed |
description | Studies have hypothesized a potential role of the interleukin (IL)-23/17 axis in coronavirus disease 2019 (COVID-19). However, to date, levels of IL-23 and 17 have not been compared between critically ill COVID-19 patients and critically ill non-COVID-19 patients. IL-23 and 17 were measured on admission to the intensive care unit (ICU) in critically ill COVID-19 (N = 38) and critically ill non-COVID-19 (N = 34) patients with an equal critical illness severity. Critically ill non-COVID-19 patients did not have sepsis or septic shock on ICU admission. None of the enrolled patients had previously received corticosteroids. In our study, circulating IL-17 levels were higher in the COVID-19 patients. More specifically, critically ill COVID-19 patients had levels of 0.78 (0.05–1.8) pg/mL compared to 0.11 (0.05–0.9) pg/mL in the critically ill non-COVID-19 patients (p = 0.04). In contrast, IL-23 levels were comparable between groups. A group of patients hospitalized in the specialized COVID-19 clinic (N = 16) was also used to evaluate IL-17 and IL-23 levels with respect to COVID-19 severity. Non-critically ill COVID-19 patients had undetectable levels of both cytokines. Our results support the notion of inhibiting IL-17 in critical COVID-19 infection. |
format | Online Article Text |
id | pubmed-8466794 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84667942021-09-27 Evaluating the Role of the Interleukin-23/17 Axis in Critically Ill COVID-19 Patients Jahaj, Edison Vassiliou, Alice G. Keskinidou, Chrysi Gallos, Parisis Vrettou, Charikleia S. Tsipilis, Stamatios Mastora, Zafeiria Orfanos, Stylianos E. Dimopoulou, Ioanna Kotanidou, Anastasia J Pers Med Communication Studies have hypothesized a potential role of the interleukin (IL)-23/17 axis in coronavirus disease 2019 (COVID-19). However, to date, levels of IL-23 and 17 have not been compared between critically ill COVID-19 patients and critically ill non-COVID-19 patients. IL-23 and 17 were measured on admission to the intensive care unit (ICU) in critically ill COVID-19 (N = 38) and critically ill non-COVID-19 (N = 34) patients with an equal critical illness severity. Critically ill non-COVID-19 patients did not have sepsis or septic shock on ICU admission. None of the enrolled patients had previously received corticosteroids. In our study, circulating IL-17 levels were higher in the COVID-19 patients. More specifically, critically ill COVID-19 patients had levels of 0.78 (0.05–1.8) pg/mL compared to 0.11 (0.05–0.9) pg/mL in the critically ill non-COVID-19 patients (p = 0.04). In contrast, IL-23 levels were comparable between groups. A group of patients hospitalized in the specialized COVID-19 clinic (N = 16) was also used to evaluate IL-17 and IL-23 levels with respect to COVID-19 severity. Non-critically ill COVID-19 patients had undetectable levels of both cytokines. Our results support the notion of inhibiting IL-17 in critical COVID-19 infection. MDPI 2021-09-07 /pmc/articles/PMC8466794/ /pubmed/34575667 http://dx.doi.org/10.3390/jpm11090891 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication Jahaj, Edison Vassiliou, Alice G. Keskinidou, Chrysi Gallos, Parisis Vrettou, Charikleia S. Tsipilis, Stamatios Mastora, Zafeiria Orfanos, Stylianos E. Dimopoulou, Ioanna Kotanidou, Anastasia Evaluating the Role of the Interleukin-23/17 Axis in Critically Ill COVID-19 Patients |
title | Evaluating the Role of the Interleukin-23/17 Axis in Critically Ill COVID-19 Patients |
title_full | Evaluating the Role of the Interleukin-23/17 Axis in Critically Ill COVID-19 Patients |
title_fullStr | Evaluating the Role of the Interleukin-23/17 Axis in Critically Ill COVID-19 Patients |
title_full_unstemmed | Evaluating the Role of the Interleukin-23/17 Axis in Critically Ill COVID-19 Patients |
title_short | Evaluating the Role of the Interleukin-23/17 Axis in Critically Ill COVID-19 Patients |
title_sort | evaluating the role of the interleukin-23/17 axis in critically ill covid-19 patients |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8466794/ https://www.ncbi.nlm.nih.gov/pubmed/34575667 http://dx.doi.org/10.3390/jpm11090891 |
work_keys_str_mv | AT jahajedison evaluatingtheroleoftheinterleukin2317axisincriticallyillcovid19patients AT vassilioualiceg evaluatingtheroleoftheinterleukin2317axisincriticallyillcovid19patients AT keskinidouchrysi evaluatingtheroleoftheinterleukin2317axisincriticallyillcovid19patients AT gallosparisis evaluatingtheroleoftheinterleukin2317axisincriticallyillcovid19patients AT vrettoucharikleias evaluatingtheroleoftheinterleukin2317axisincriticallyillcovid19patients AT tsipilisstamatios evaluatingtheroleoftheinterleukin2317axisincriticallyillcovid19patients AT mastorazafeiria evaluatingtheroleoftheinterleukin2317axisincriticallyillcovid19patients AT orfanosstylianose evaluatingtheroleoftheinterleukin2317axisincriticallyillcovid19patients AT dimopoulouioanna evaluatingtheroleoftheinterleukin2317axisincriticallyillcovid19patients AT kotanidouanastasia evaluatingtheroleoftheinterleukin2317axisincriticallyillcovid19patients |